Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature
Tóm tắt
Strategies for screening and intervening to reduce the risk of cardiovascular disease (CVD) in primary care settings need to be assessed in terms of both their costs and long-term health effects. We undertook a literature review to investigate the methodologies used.
In a framework of developing a new health-economic model for evaluating different screening strategies for primary prevention of CVD in Europe (EPIC-CVD project), we identified seven key modeling issues and reviewed papers published between 2000 and 2013 to assess how they were addressed. We found 13 relevant health-economic modeling studies of screening to prevent CVD in primary care. The models varied in their degree of complexity, with between two and 33 health states. Programmes that screen the whole population by a fixed cut-off (e.g., predicted 10-year CVD risk >20 %) identify predominantly elderly people, who may not be those most likely to benefit from long-term treatment. Uncertainty and model validation were generally poorly addressed. Few studies considered the disutility of taking drugs in otherwise healthy individuals or the budget impact of the programme. Model validation, incorporation of parameter uncertainty, and sensitivity analyses for assumptions made are all important components of model building and reporting, and deserve more attention. Complex models may not necessarily give more accurate predictions. Availability of a large enough source dataset to reliably estimate all relevant input parameters is crucial for achieving credible results. Decision criteria should consider budget impact and the medicalization of the population as well as cost-effectiveness thresholds.
Tài liệu tham khảo
Leal, J., Luengo-Fernandez, R., Gray, A., Petersen, S., Rayner, M.: Economic burden of cardiovascular diseases in the enlarged European Union. Eur. Heart J. 27(13), 1610–1619 (2006)
Goff Jr, D.C., Lloyd-Jones, D.M., Bennett, G., Coady, S., D’Agostino, R.B., Gibbons, R., et al.: ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl 2), S49–S73 (2014). doi:10.1161/01.cir.0000437741.48606.98. (Epub 2013 Nov 12)
Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H., et al.: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl 2), S1–S45 (2014). doi:10.1161/01.cir.0000437738.63853.7a. (Epub 2013 Nov 12)
Eckel, R.H., Jakicic, J.M., Ard, J.D., de Jesus, J.M., Houston Miller, N., Hubbard, V.S., et al.: 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl 2), S76–S99 (2014). doi:10.1161/01.cir.0000437740.48606.d1. (Epub 2013 Nov 12)
Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, M., et al.: European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 33(13), 1635–1701 (2012)
Public Health England. NHS Health Check: our approach to the evidence. http://www.healthcheck.nhs.uk/document.php?o=346 (2013) Accessed Feb 2014
National Clinical Guideline Centre. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London (UK): National Institute for Health and Care Excellence (NICE), p. 50 (Clinical guideline; no. 181). http://www.nice.org.uk/guidance/cg181/resources/guidance-lipid-modification-cardiovascular-risk-assessment-and-the-modification-of-blood-lipids-for-the-primary-and-secondary-prevention-of-cardiovascular-disease-pdf (2014) Accessed Oct 2014
Marshall, T.: Evaluating national guidelines for prevention of cardiovascular disease in primary care. J. Eval. Clin. Pract. 11(5), 452–461 (2005)
Murray, C.J., Lauer, J.A., Hutubessy, R.C., Niessen, L., Tomijima, N., Rodgers, A., et al.: Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 361, 717–725 (2003)
Chamnan, P., Simmons, R.K., Khaw, K.T., Wareham, N.J., Griffin, S.J.: Estimating the potential population impact of stepwise screening strategies for identifying and treating individuals at high risk of Type 2 diabetes: a modelling study. Diabet. Med. 29(7), 893–904 (2012)
Abramson, J.D., Rosenberg, H.G., Jewell, N., Wright, J.M.: Should people at low risk of cardiovascular disease take a statin? Br. Med. J. 347, f6123 (2013)
Mihaylova BBA.: The Cost-Effectiveness of Statin Treatment: Can We Synthesize Evidence From Economic Evaluations? Oxford: Health Economics Research Centre, University of Oxford. http://www.herc.ox.ac.uk/conferences-and-presentations/20012002presentationfilelinks/bm1201 (2001). Accessed Jan 2014
Ara, R., Basarir, H., Ward, S.E.: Principles of health economic evaluations of lipid-lowering strategies. Curr. Opin. Lipidol. 23(4), 271–281 (2012)
Neyt, M., De Laet, C., Van Brabandt, H., Franco, O., Ramaekers, D.: Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium. Acta Cardiol. 64(1), 1–10 (2009)
Franco, O.H., Peeters, A., Looman, C.W.N., Bonneux, L.: Cost effectiveness of statins in coronary heart disease. J. Epidemiol. Community Health 59(11), 927–933 (2005)
Mitchell, A.P., Simpson, R.J.: Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States. BMC Res. Notes 5, 373 (2012)
Schwappach, D.L.B., Boluarte, T.A., Suhrcke, M.: The economics of primary prevention of cardiovascular disease: a systematic review of economic evaluations. Cost Eff. Resour. Alloc. 5, 5 (2007)
Blake, G.J., Ridker, P.M., Kuntz, K.M.: Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am. J. Med. 114(6), 485–494 (2003)
Johannesson, M.: At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur. Heart J. 22(11), 919–925 (2001)
Marshall, T., Rouse, A.: Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study. BMJ 325(7357), 197 (2002)
Pletcher, M.J., Lazar, L., Bibbins-Domingo, K., Moran, A., Rodondi, N., Coxson, P., et al.: Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann. Intern. Med. 150(4), 243–254 (2009)
Kok, L., Engelfriet, P., Jacobs-van der Bruggen, M., Hoogenveen, R.T., Boshuizen, H.C., Verschuren, M.W.: The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands. Eur. J. Cardiovasc. Prev. Rehabil. 16(3), 371–376 (2009)
Rapsomaniki, E., White, I.R., Wood, A.M., Thompson, S.G.: A framework for quantifying net benefits of alternative prognostic models. Stat. Med. 31(2), 114–130 (2012)
Wald, N.J., Simmonds, M., Morris, J.K.: Screening for future cardiovascular disease using age alone compared with multiple risk factors and age. PLoS ONE 6(5), e18742 (2011)
Choudhry, N.K., Patrick, A.R., Glynn, R.J., Avorn, J.: The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J. Am. Coll. Cardiol. 57(7), 784–791 (2011)
Lovibond, K., Jowett, S., Barton, P., Caulfield, M., Heneghan, C., Hobbs, F.D., et al.: Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet 378(9798), 1219–1230 (2011)
Cobiac, L.J., Magnus, A., Barendregt, J.J., Carter, R., Vos, T.: Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study. BMC Public Health 12(1), 398 (2012)
Shiffman, D., Slawsky, K., Fusfeld, L., Devlin, J.J., Goss, T.F.: Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease. Clin. Ther. 34(6), 1387–1394 (2012)
den Ruijter, H.M., Vaartjes, I., Sutton-Tyrrell, K., Bots, M.L., Koffijberg, H.: Long-term health benefits and costs of measurement of carotid intima-media thickness in prevention of coronary heart disease. J. Hypertens. 31(4), 782–790 (2013)
Lee, K.K., Cipriano, L.E., Owens, D.K., Go, A.S., Hlatky, M.A.: Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation 122, 1478–1487 (2010)
Paris, V., Belloni, A.: Value in Pharmaceutical pricing. OECD Health Working Paper No. 63 (2013)
Ridker, P.M., Cook, N.R.: Statins: new American guidelines for prevention of cardiovascular disease. Lancet 382(9907), 1762–1765 (2013)
Caro, J.J., Nord, E., Siebert, U., et al.: The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ. 19(10), 1117–1127 (2010)
Karnon, J., Stahl, J., Brennan, A., Caro, J.J., Mar, J., Moller, J.: Modeling using discrete event simulation: a report of the ISPOR-SMDM modeling good research practices task force-4. Med. Decis. Making 32(5), 701–711 (2012)
van Kempen, B.J.H., Ferket, B.S., Hofman, A., Spronk, S., Steyerberg, E., Hunink, M.G.M.: Do different methods of modeling statin treatment effectiveness influence the optimal decision? Med. Decis. Making 32(3), 507–516 (2012)
D’Agostino, R.B., Vasan, R.S., Pencina, M.J., Wolf, P.A., Cobain, M., Massaro, J.M., et al.: General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 118(4), E86 (2008)
Anderson, K., Odell, P., Wilson, P., Kannel, W.: Cardiovascular disease risk profiles. Am. Heart J. 121, 293–298 (1991)
Beswick, A.D., Brindle, P., Fahey, T., Ebrahim, S.: A Systematic Review of Risk Scoring Methods and Clinical Decision Aids Used in the Primary Prevention of Coronary Heart Disease (Supplement) [Internet]. Royal College of General Practitioners (UK), London (2008)
Korn, E.L., Graubard, B.I., Midthune, D.: Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am. J. Epidemiol. 145(1), 72–80 (1997)
Collett, D.: Modelling Survival Data in Medical Research, 2nd edn. Chapman & Hall/CRC, Boca Raton (2003)
Mcneil, J.J., Peeters, A., Liew, D., Lim, S., Vos, T.: A model for predicting the future incidence of coronary heart disease within percentiles of coronary heart disease risk. J. Cardiovasc. Risk 8(1), 31–37 (2001)
Caro, J.J., Briggs, A.H., Siebert, U., Kuntz, K.M.: Modeling good research practices-overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Health 15(6), 796–803 (2012)
Claxton, K., Walker, W., Palmer, S., Sculpher, M.: Appropriate Perspectives for Health Care Decisions. CHE Research Paper 54. Centre for Health Economics, University of York (2010)
Putter, H., Fiocco, M., Geskus, R.B.: Tutorial in biostatistics: competing risks and multi-state models. Stat. Med. 26(11), 2389–2430 (2007)
Brennan, A., Akehurst, R.: Modelling in health economic evaluation: What is its place? What is its value? Pharmacoeconomics 17(5), 445–459 (2000)
Spiegelhalter, D.J., Best, N.G., Carlin, B.R., van der Linde, A.: Bayesian measures of model complexity and fit. J. R. Stat. Soc. Ser. B Stat. Methodol. 64, 583–616 (2002)
Briggs, A.H., Weinstein, M.C., Fenwick, E.A.L., Karnon, J., Sculpher, M.J., Paltiel, A.D.: Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling good research practices task force working group-6. Med. Decis. Making 32(5), 722–732 (2012)